Literature DB >> 15056082

Can we immunogenotypically and immunophenotypically profile patients who are at risk for pouchitis?

Bo Shen, Bret Lashner.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15056082     DOI： 10.1111/j.1572-0241.2004.04096.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  4 in total

1.  Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis.

Authors:  K M Lammers; S Ouburg; S A Morré; J B A Crusius; P Gionchett; F Rizzello; C Morselli; E Caramelli; R Conte; G Poggioli; M Campieri; A S Peña
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 2.  Use of Biologics in Pouchitis: A Systematic Review.

Authors:  Hans H Herfarth; Millie D Long; Kim L Isaacs
Journal:  J Clin Gastroenterol       Date:  2015-09       Impact factor: 3.062

3.  Vedolizumab in the treatment of Crohn's disease of the pouch.

Authors:  Freeha Khan; Xian-Hua Gao; Amandeep Singh; Jessica R Philpott; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-06-22

4.  Vedolizumab for chronic antibiotic-refractory pouchitis.

Authors:  Amandeep Singh; Freeha Khan; Rocio Lopez; Bo Shen; Jessica Philpott
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.